The AdenoPlus test is designed to detect adenovirus. Nicox said the test is a four-step process that takes less than two minutes to complete and provides a result in 10 minutes.
“With AdenoPlus, Nicox has taken a first step towards fulfilling its objective of starting a commercial business in the ophthalmic space,” said Michele Garufi, chairman and CEO of Nicox, in the release. “We have established a specialized sales team on the ground who will be marketing and selling this innovative and easy-to-use product to eyecare practitioners across the United States, bringing a new, fast and accurate diagnostic option that will aid in the differential diagnosis of acute conjunctivitis.”
Nicox is headquartered in France, and has a U.S. subsidiary in Dallas.
Related Articles on New Technology:
Boston Scientific Launches Guidewire for Crossing Resistant Lesions
PENTAX Set to Launch New Endoscopic Imaging Platform
Vidacare Launches New Accessory Tray for Bone Lesion Access and Biopsy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
